Javascript must be enabled to continue!
Restless legs syndrome is associated with cardio/cerebrovascular events and mortality in end‐stage renal disease
View through CrossRef
Background and purposeEarlier studies suggested an association between idiopathic restless legs syndrome (RLS) and cardiovascular diseases. However, the risk of cardiovascular events in patients with secondary RLS due to end‐stage renal disease (ESRD) is unclear. Our aim was to examine whether ESRD patients with RLS had an increased risk of cardio/cerebrovascular events and mortality.MethodsIn all, 1093 ESRD patients were recruited between 2009 and 2010. The diagnosis and severity of RLS were assessed in a face‐to‐face interview. The occurrence of cardio/cerebrovascular events and death were confirmed by medical record review. The association between RLS and the outcomes of interest was examined using an adjusted multivariate Cox regression model.ResultsAfter a mean follow‐up period of 3.7 ± 0.8 years, ESRD patients with RLS had a significantly higher risk of developing cardiovascular events and strokes [adjusted hazard ratio (aHR) 2.82, 95% confidence interval (CI) 2.02–4.11, and aHR 2.41, 95% CI 1.55–3.75, respectively] compared with patients without RLS. Increasing RLS severity was associated with an increasing likelihood of cardiovascular events [mild RLS severity, aHR 1.71 (95% CI 1.02–2.87); moderate, 2.79 (1.64–4.66); severe, 2.85 (1.99–4.46)] and strokes [mild, 1.89 (0.87–4.16); moderate, 2.42 (1.50–3.90); severe, 2.64 (1.49–4.91)] in a dose‐dependent manner. RLS also increased the risk of total mortality in patients with ESRD [aHR 1.53 (95% CI 1.07–2.18), P = 0.02]; this association attenuated slightly after stratification by individual RLS severity category [mild RLS severity, aHR 1.44 (95% CI 0.78–2.67); moderate, 1.49 (0.98–2.55); severe, 2.03 (0.93–4.45)].ConclusionsESRD patients with RLS demonstrated an increased likelihood of cardio/cerebrovascular events and mortality.
Title: Restless legs syndrome is associated with cardio/cerebrovascular events and mortality in end‐stage renal disease
Description:
Background and purposeEarlier studies suggested an association between idiopathic restless legs syndrome (RLS) and cardiovascular diseases.
However, the risk of cardiovascular events in patients with secondary RLS due to end‐stage renal disease (ESRD) is unclear.
Our aim was to examine whether ESRD patients with RLS had an increased risk of cardio/cerebrovascular events and mortality.
MethodsIn all, 1093 ESRD patients were recruited between 2009 and 2010.
The diagnosis and severity of RLS were assessed in a face‐to‐face interview.
The occurrence of cardio/cerebrovascular events and death were confirmed by medical record review.
The association between RLS and the outcomes of interest was examined using an adjusted multivariate Cox regression model.
ResultsAfter a mean follow‐up period of 3.
7 ± 0.
8 years, ESRD patients with RLS had a significantly higher risk of developing cardiovascular events and strokes [adjusted hazard ratio (aHR) 2.
82, 95% confidence interval (CI) 2.
02–4.
11, and aHR 2.
41, 95% CI 1.
55–3.
75, respectively] compared with patients without RLS.
Increasing RLS severity was associated with an increasing likelihood of cardiovascular events [mild RLS severity, aHR 1.
71 (95% CI 1.
02–2.
87); moderate, 2.
79 (1.
64–4.
66); severe, 2.
85 (1.
99–4.
46)] and strokes [mild, 1.
89 (0.
87–4.
16); moderate, 2.
42 (1.
50–3.
90); severe, 2.
64 (1.
49–4.
91)] in a dose‐dependent manner.
RLS also increased the risk of total mortality in patients with ESRD [aHR 1.
53 (95% CI 1.
07–2.
18), P = 0.
02]; this association attenuated slightly after stratification by individual RLS severity category [mild RLS severity, aHR 1.
44 (95% CI 0.
78–2.
67); moderate, 1.
49 (0.
98–2.
55); severe, 2.
03 (0.
93–4.
45)].
ConclusionsESRD patients with RLS demonstrated an increased likelihood of cardio/cerebrovascular events and mortality.
Related Results
Migraine and Restless Legs Syndrome: A Meta‐Analysis
Migraine and Restless Legs Syndrome: A Meta‐Analysis
ABSTRACTRestless legs syndrome is a sensorimotor disorder of sleep/wake regulation that frequently coexists with migraine, affecting patients' quality of life. This study aimed to ...
Complex Collision Tumors: A Systematic Review
Complex Collision Tumors: A Systematic Review
Abstract
Introduction: A collision tumor consists of two distinct neoplastic components located within the same organ, separated by stromal tissue, without histological intermixing...
Frequency and severity of restless leg syndrome in healthcare professionals
Frequency and severity of restless leg syndrome in healthcare professionals
Objective: To determine the frequency and severity of restless leg syndrome in healthcare professionals.
Study design: It was a descriptive cross sectional study.
Place and durat...
Chinese herbal injection for cardio-cerebrovascular disease: Overview and challenges
Chinese herbal injection for cardio-cerebrovascular disease: Overview and challenges
Cardio-cerebrovascular diseases are the leading cause of death worldwide and there is currently no optimal treatment plan. Chinese herbal medicine injection (CHI) is obtained by co...
Cabergoline - Dopamine Receptor Agonist
Cabergoline - Dopamine Receptor Agonist
Background: Cabergoline is a potent dopamine receptor agonist used primarily for the treatment of disorders related to dopamine dysregulation. It acts by stimulating dopamine recep...
Three in One: Systemic Lupus Erythematosus, HELLP Syndrome, and Antiphospholipid Syndrome: A Case Report and Literature Review
Three in One: Systemic Lupus Erythematosus, HELLP Syndrome, and Antiphospholipid Syndrome: A Case Report and Literature Review
Abstract
Introduction
Systemic lupus erythematosus (SLE) is a multisystem autoimmune disease commonly affecting women of reproductive age. Its overlap with HELLP syndrome (Hemolysi...
Fregoli Syndrome: A Case Report and Literature Review
Fregoli Syndrome: A Case Report and Literature Review
Abstract
Introduction: Fregoli syndrome is a rare misidentification disorder that can disrupt behavior, endanger safety, and impair quality of life. Its occurrence in young adults ...
Small Cell Lung Cancer and Tarlatamab: A Meta-Analysis of Clinical Trials
Small Cell Lung Cancer and Tarlatamab: A Meta-Analysis of Clinical Trials
Abstract
Introduction
Tarlatamab is a Delta-like ligand 3 (DLL3) -directed bispecific T-cell engager recently approved for use in patients with advanced small cell lung cancer (SCL...

